NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Johnson & Johnson (NYSE:JNJ) said it has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder cancer, or MIBC, due to disappointing data. The drugmaker had ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...